Authors: Ming C. Liau, Christine L. Craig, Linda L. Baker.
The objective of this article is to develop CDA formulations to reduce cancer mortality. In 2022, President Joe Biden of the USA asked the health profession to reduce mortality of cancer patients by 50 % in the following 25 years which was a modest request in comparison to the war on cancer declared by President Nixon in 1971. Cancer is a giant issue of national interest for presidents to get involved. The health profession is hapless to solve this issue. The incidence and the mortality of cancer continued to increase since these statistics became public records. Cancer mortality in the USA has reached 0.61 million in 2023 and around the world has reached 10 million in 2019. The ever increasing records of cancer mortality are an indication of the failure of the health profession to solve cancer.
Cancer is caused by wound unhealing due to the collapse of chemo-surveillance. Wound healing requires the proliferation and the terminal differentiation of progenitor stem cells (PSCs), which are the embryonic stem cells to initiate the development of organs or tissues, and also the cells responsible for wound healing. Methylation enzymes (MEs) of embryonic stem cells are abnormal due to association with telomerase, which gives cells with abnormal MEs a great advantage on cell growth. Cell growth is, obviously, needed for the development of fetus and wound healing. The nature creates safety mechanisms such as contact inhibition, ten eleven translocator-1 (TET-1) enzyme to direct lineage transitions and chemo-surveillance to prevent the buildup of cells with abnormal MEs to become clinical problems. When such safety mechanisms fail, clinical symptoms evolve. Cancer is one of these clinical problems. So, the correct solution of cancer is to heal wound, which we advocate. The cancer establishments preferred cell killing to eliminate tumor mass, which is opposite to healing wound by creating wounds to aggravate the already bad situation to result in ever increasing cancer mortality. Cancer mortality is the ultimate judgment on the success of cancer therapy. Cytotoxic agents approved by cancer establishments can cure cancer patients in the early stage relying on the restoration of chemo-surveillance to subdue surviving CSCs, but contribute to the deaths of advanced cancer patients whose chemo-surveillance have been fatally damaged, whereas cell differentiation agent (CDA) formulations can save all cancer patients to reduce cancer mortality. Therefore, CDA formulations are the only viable option to fulfill President Biden’s order to save cancer patients.
View/Download pdf